125080-07-1Relevant academic research and scientific papers
Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists
Ladouceur, Gaetan H.,Cook, James H.,Doherty, Elizabeth M.,Schoen, William R.,MacDougall, Margit L.,Livingston, James N.
, p. 461 - 464 (2002)
5-Hydroxyalkyl-4-phenylpyridines have been identified as a novel class of glucagon antagonists with potential utility for the treatment of diabetes. A lead structure with moderate activity was discovered through a high throughput screening assay. Structure-activity relationships led to the discovery of a potent antagonist, IC50=0.11 μM, more than 60-fold improvement over the lead structure.
Certain 2,6-diisopropyl-4-(4-fluoro-phenyl)-3,5-bis-dimethyl-3',5'-dihydroxy-hept-6-enoate-pyridine derivatives useful for treating lipoproteinaemia and arteriosclerosis
-
, (2008/06/13)
For the treatment of lipoproteinaemia and arteriosclerosis, the new disubstituted pyridines of the formula STR1 in which R1 is optionally substituted aryl or heteroaryl, R2 is cycloalkyl or optionally substituted alkyl, R3
